title: Erlotinib induced ectropion following papulopustular rash.
abstract: BACKGROUND
  Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR).
  
  
  METHODS
  A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy.
  
  
  CONCLUSIONS
  EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.
authors.affiliation: Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey;
authors.forename: Andac
authors.initials: A
authors.lastname: Salman
authors.affiliation: Marmara University School of Medicine, Department of Ophthalmology, Istanbul, Turkey;
authors.forename: Eren
authors.initials: E
authors.lastname: Cerman
authors.affiliation: Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey;
authors.forename: Dilek
authors.initials: D
authors.lastname: Seckin
authors.affiliation: Marmara University School of Medicine, Department of Oncology, Istanbul, Turkey.
authors.forename: Metin
authors.initials: M
authors.lastname: Kanitez
keywords: adverse effects; ectropion; erlotinib; eye; papulopustular rash